XM
CHRS icon

XTX Markets’s Coherus Oncology CHRS Stock Holding History

XTX Markets’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,002
Closed -$183K – 202
2020
Q3 		$183K Buy
+10,002
New +$186K 0.88% 65

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

XTX Markets's CHRS Position: Q4 2020 in Review

XTX Markets sold out of Coherus Oncology (CHRS) in Q4 2020, closing a stake of 10,002 shares — an estimated $183K sold.

XTX Markets first reported a position in CHRS in Q3 2020 and held it in 1 quarter. The position peaked at $183K in Q3 2020. 196 funds tracked by Wall St. Rank hold CHRS as of Q4 2020.

  • XTX Markets reported no remaining Coherus Oncology position as of Q4 2020 after selling out during the quarter.
  • XTX Markets sold 10,002 Coherus Oncology shares in Q4 2020, an estimated $183K.
  • XTX Markets first reported a position in Coherus Oncology in Q3 2020 and held it in 1 quarter.
  • XTX Markets's Coherus Oncology position peaked at $183K in Q3 2020.
  • 196 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2020.

Based on XTX Markets's 13F filing for Q4 2020, filed 25 Jan 2021.